I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Basal insulin secretion constitutes approximately 40% of the total insulin secretion over a 24-hour period and inhibits hepatic glycogenolysis, ketogenesis, and gluconeogenesis.\[[@ref1]\] Several trials have highlighted the increasing role of basal insulin in the management of diabetes mellitus leading to the search for the ideal basal insulin.\[[@ref2][@ref3][@ref4][@ref5]\]

Previously, it was discovered that the duration of action of insulin could be prolonged through addition of zinc and combination with strongly basic proteins (e.g. protamine). The first basal insulin, Neutral Protamine Hagedorn insulin (NPH), originally consisted of insulin and protamine with small amounts of zinc and phenol at neutral pH, but later formulations were produced by adding protamine to recombinantly synthesized human insulin. NPH was originally considered long-acting insulin even though its duration of action was only 12--18 hours. NPH shows a pronounced peak effect, which can increase risk of nocturnal hypoglycemia.\[[@ref6]\] It fails to mimic the physiological profile and is associated with excess variability in absorption and action and may need to be administered twice or even thrice daily.\[[@ref2][@ref7]\] A higher level of hypoglycemia and nocturnal hypoglycemia in particular, remains a major limitation of NPH. Inadequate re-suspension of NPH, which is quite common, may contribute to higher variability and hence, identical doses of subcutaneous insulin do not always lead to the same glycemic effect.\[[@ref8]\] Therefore, there was a strong need to develop insulin without such pharmacokinetic and pharmacodynamic (PK/PD) inconsistencies and hence, long-acting (basal) insulin analogs were developed to provide a more physiologic PK/PD profile with longer duration of action, less intra-patient variability, less pronounced peak in time-action profiles, and lesser hypoglycemic risk compared with NPH.\[[@ref9]\]

Modern basal analogs such as insulin detemir and insulin glargine both have a longer duration of action and a flatter profile than NPH. Both have a longer duration of action, less intra-patient variability, less pronounced peak in time-action profiles, and decreased hypoglycemic risk than NPH; however, even these insulin analogs do not last for 24 hours in some patients, requiring up to two injections to achieve glycemic control.\[[@ref6][@ref10][@ref11][@ref12][@ref13][@ref14]\] It is estimated that approximately 40% of type 1 patients still require twice daily injections of long-acting insulin analogs such as glargine, and these patients in particular could benefit from newer basal insulin options with longer time-action profiles.\[[@ref15][@ref16]\]

It would be worthwhile to note that just prolonging the half life of basal insulin may not merely yield a clinical benefit. These lessons can be learnt from the studies with bovine-NPH and ultra-lente insulin. Though both had much longer half life of approximately 36 hours, bovine-NPH had very poor bio-availability requiring very high doses and ultra-lente had a very peculiar property of erratic absorption leading to labile blood glucose swings. Both are no longer available for clinical use and hence, it may be concluded that longer-acting basal insulin may not necessarily be better. Therefore, the need of hour is to have a long-acting insulin (with a duration of action of at least 24 hours) with good biological properties.\[[@ref17]\]

Adequate data is now available with the recent publication of phase IIIa studies of newer longer-acting basal insulin analogs including insulin degludec and insulin glargine U-300. Some data are also emerging from phase II studies of yet another newer basal analog called pegylated insulin-lispro \[[Figure 1](#F1){ref-type="fig"}\].

![Evolvement of modern basal insulin analogues](IJEM-18-784-g001){#F1}

Insulin degludec is a neutral, soluble, ultra-long-acting basal insulin analog with duration of action found to be \>42 hour in patients with type 1 diabetes. It has a mean elimination half-life of approximately 25 hours.\[[@ref18]\] Steady state is reached in 2-3 days with subcutaneous administration of once-daily insulin degludec \[[Table 1](#T1){ref-type="table"}\]. At steady state, there was no day-to-day change in overall exposure for insulin degludec.\[[@ref19]\] Within-subject variability of insulin degludec is four times less compared to glargine and in fact, is the least compared to all available basal insulins\[[@ref14][@ref20][@ref21]\] \[[Figure 2](#F2){ref-type="fig"}\]. The degradation of insulin degludec is similar to that of human insulin, with all metabolites being inactive. The primary route of elimination of insulin degludec is via degradation at the insulin receptor, which is independent of dose.\[[@ref20]\]

###### 

Summary of the properties of insulin degludec
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![Glycemic variability of basal insulin. Within-subject variability in pharmacodynamic endpoints for insulin detemir versus NPH versus glargine and insulin glargine versus degludec in patients with type 1 diabetes undergoing euglycemic clamp trial. The dose administered was 0.4 IU/kg.](IJEM-18-784-g003){#F2}

Comparison of any insulin trial including basal insulin has certain limitations. The most crucial limitation for any insulin trial is its open-label design as they cannot be single-blinded let alone double-blinded. This open-label design of insulin makes it difficult to prevent investigator-dependent bias and may influence the study protocol for desired outcomes. If one treatment is found to be superior over other, it could be possible that the drug in question is superior or the protocol is superior or both. Therefore, all comparative insulin trials must be interpreted in the light of these limitations. Also, with the passage of time, these modern basal analogs have been peppered with complicated and ever-changing rules and regulations. Ideally, the same sets of outcome measures should have been applied for the studies comparing all basal insulin; however, with the recent changes in regulations and a different outcome measures set in later studies, it is becoming more difficult to reach any meaningful conclusion.

This review will attempt to provide a simple, comprehensive, comparative, and critical assessment of these currently available basal insulin analogs.

T[HE]{.smallcaps} G[LARGINE]{.smallcaps} S[TORY]{.smallcaps} {#sec1-2}
============================================================

When glargine was seeking approval to USFDA from their phase III trials (typically named study A to I in both type 1 and type 2 diabetes), they could not establish any superiority of glargine over NPH in any parameters including comparative efficacy and safety. There was no difference in A1c and fasting blood sugar (FBS) at the end of these head-to-head studies.\[[@ref22]\] As these studies were not typical treat-to-target trials, no data was generated highlighting any meaningful differences in total insulin dose or total basal dose at the end of studies. Although there were no differences in hypoglycemic parameters between the two basal insulins, surprisingly, two of the studies (study C and study E) with glargine showed higher trends of hypoglycemia compared to NPH. Overall, the glargine arm had significantly higher (4 times) pain at injection site compared to NPH across all the studies. Hypoglycemia was also defined as blood sugar \< 50 mg/dl in majorities of these head-to-head trials except study G (\<56 mg/dl). Finally, none of these studies looked for any hard end points including cardiovascular (CV) safety, as it was not required for approval during that point of time but glargine received FDA approval\[[@ref22]\] \[[Table 2](#T2){ref-type="table"}\]. It should be noted that most of these trials used NPH twice daily.

###### 

Comparing Glargine Vs NPH trials (Pre-FDA approval data)^@^
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While there was no clear benefit during pre-approval data of glargine over NPH, subsequent post-FDA approval studies \[[Table 3](#T3){ref-type="table"}\] and their meta-analysis \[[Table 4](#T4){ref-type="table"}\] did show significant benefit of glargine over NPH based mainly on hypoglycemia outcome, especially nocturnal hypoglycemia.\[[@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37][@ref38]\] Some studies also showed benefit in A1c and FBS reduction compared to NPH. Finally, a CV trial of glargine, Outcome Reduction with an Initial Galrgine Intervention (ORIGIN) trial showed CV neutrality of glargine over 6.2 years.\[[@ref39]\]

###### 

Comparing Glargine vs. NPH trials (post-FDA approval data)
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###### 

Hypoglycemia outcome from meta-analysis of randomized trials (Glargine Vs NPH)

![](IJEM-18-784-g006)
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Detemir also requested USFDA approval from their phase III trials (typically named study A to F in both type 1 and type 2 diabetes). They also could not establish superiority over NPH in any parameters including comparative safety and efficacy \[[Table 5](#T5){ref-type="table"}\]. There was no difference in A1c and FBS at the end of these head-to-head studies.\[[@ref40]\] As these studies were not typical treat-to-target trials, again no data was generated towards any meaningful differences in total insulin dose or total basal dose at the end of these studies. In general, there were no differences in hypoglycemia outcome between these two insulins. Overall, NPH showed higher trends of hypoglycemia compared to detemir but surprisingly in two of these studies (studies A and C) detemir showed higher trend of severe hypoglycemia compared to NPH. Hypoglycemia was defined as blood glucose of \<50 mg/dl (plasma glucose \< 56 mg/dl).\[[@ref40]\] Finally, none of these studies looked for hard end points including CV safety, as it was not required for approval during that point of time but detemir received FDA approval. It should be noted again that the majority of these trials used NPH twice daily.

###### 

Comparison of Detemir Vs NPH/Glargine trials (Pre-FDA approval data)
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While there was no clear benefit during pre-approval data of detemir over NPH, the latter post-approval \[[Table 6](#T6){ref-type="table"}\] studies and their meta-analysis \[[Table 7](#T7){ref-type="table"}\] did show significant benefit of detemir over NPH mainly on hypoglycemia outcome, especially nocturnal hypoglycemia. Some studies also showed benefit in A1c and FBS reduction compared to NPH.\[[@ref13][@ref41][@ref42][@ref43][@ref44][@ref45][@ref46][@ref47][@ref48][@ref49][@ref50][@ref51][@ref52][@ref53][@ref54][@ref55][@ref56][@ref57]\] Detemir has not been involved in CV trials so far to show any hard end point reduction or prove CV neutrality, as seen with glargine in ORIGIN trial.

###### 

Comparison of detemir Vs NPH trials (post-FDA approval data)

![](IJEM-18-784-g008)

###### 

Meta-analysis of randomized trials (detemir versus NPH)
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============================================================

Degludec is newer ultra-long-acting basal analog seeking USFDA approval based on their phase III trials (typically named BEGIN trials) comparing head-to-head against glargine and detemir \[[Table 8](#T8){ref-type="table"}\]. Majority of these phase III pre-approval studies and their meta-analysis suggested a significant improvement in nocturnal hypoglycemia compared to glargine (glargine and detemir, however, could not prove any improvement in hypoglycemia outcomes in their pre-approval studies over NPH). As all these studies are primarily treat-to-target, there were no differences in A1c at the end but some of the studies suggested a better FBS control and required lesser doses (10-12%) when compared to glargine.\[[@ref58][@ref59][@ref60][@ref61][@ref62][@ref63][@ref64][@ref65][@ref66][@ref67]\]

###### 

Comparison of degludec Vs glargine trial (pre-FDA approval data)
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However, these head-to-head degludec versus glargine trials must be interpreted in the light of certain limitations. Firstly, the target to achieve fasting glucose of \<90 mg/dl is too ambitious a goal and not widely practiced in reality; therefore, the minimal hypoglycemic benefit achieved with one agent may not be largely substantial in real world settings. Secondly, degludec was always administered with the main evening meal whereas insulin glargine could be given (per label) at any time of day in these studies. This disparity between timings of injection might have confounded the nocturnal hypoglycemia outcome. Finally, the cost-effectiveness of degludec could be another area of argument. Although a short-term economic model evaluating the cost-effectiveness of degludec versus glargine in type 2 diabetes suggested its benefit in patients suffering from recurrent hypoglycemia, the overall cost benefit in the entire spectrum of diabetes is yet to be evaluated.

Interestingly, the criteria used to define hypoglycemia and nocturnal timings in these head-to-head studies, received criticism from USFDA. Notably, ADA defines hypoglycemia as blood sugar \< 70 mg/dl, and none of these degludec studies followed this ADA principle. However, in reality, neither of the earlier basal insulin studies carried out so far with glargine and detemir used these ADA criteria in their pre-approval studies when compared to NPH (possibly because these definitions emerged later). However, when this ADA criterion of hypoglycemia was applied to these degludec head-to-head studies against glargine, the margin of benefits showed a reduction but still remained significant in quite a few studies \[[Table 9](#T9){ref-type="table"}\]. When nocturnal timings were changed by 2 hours on either side of Novo-Nordisk timings (as stated by FDA), the margin of benefit was reduced but nevertheless still persisted in some studies \[[Table 10](#T10){ref-type="table"}\].\[[@ref68][@ref69]\]

###### 

Hypoglycemia definition and nocturnal hypoglycemia rate ratios IDeg/IGlar
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###### 

Different definitions of nocturnal timing and nocturnal hypoglycemia rate ratios IDeg/IGlar
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Subsequently, FDA reviews board have not yet approved degludec based upon their updated data, which showed increase in major adverse cardiac events (MACE) by 33% when unstable angina was excluded from original dataset, other regulators such European agency (EMA), Japan FDA, and many other countries including Mexico and India have already given their approval to degludec based on the same original data. FDA will likely reconsider its approval once further updated data in this regard is placed. Nevertheless, it is evident that when unstable angina was not excluded from the original data set of the pre-approved protocol, MACE events were not found to be raised with degludec \[[Table 11](#T11){ref-type="table"}\]. It is also unclear as to why FDA decided to exclude unstable angina from MACE.\[[@ref68][@ref69]\]

###### 

Pooled hazard ratio estimates for MACE
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However, an area that needs further clarification about degludec is the effect of over-insulinization and its consequences on CV effect and mitogenecity in the long term. Generally, in insulin-treated persons with type 2 diabetes, it is standard to recommend that plasma insulin concentrations remain within a 50-200 pmol/L range in order to avoid over-insulinization. Such concentrations are achieved when daily doses of insulin glargine or NPH insulin approximate 0.4 units/kg. However, the total plasma insulin concentrations are much greater in persons treated with insulin degludec. As this insulin derives its protracted action from the insertion of a long chain fatty acid moiety to the insulin molecule, thereby increasing albumin binding, consequently in persons with type 2 diabetes, stable total plasma concentrations as high as 6000 pmol/L are observed for insulin degludec.\[[@ref70]\] At present, the free to bound ratio of plasma insulin concentrations remains unknown for this insulin. Currently, we need to fully understand as to how this insulin is eliminated or degraded and to quantify the respective contributions of the free and bound fractions. Lastly, a prospective CV studies with degludec in line with the ORIGIN study will actually throw some light and possibly clarify some of these issues.\[[@ref71]\]

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

The struggle to find the ideal basal insulin continues. NPH has a short half life, has to be injected twice, has a higher variability, and with higher hypoglycemia. The biggest advantage with NPH is the ability to mix with other insulin. Glargine is a definite improvement over NPH, being longer acting, used once daily, with much lesser variability, and lesser nocturnal hypoglycemia compared to NPH. Detemir is even more improvised technically with lesser variability, lesser nocturnal hypoglycemia, and lesser weight gain compared to glargine, but detemir often needs twice daily injection and much larger doses. Both glargine and detemir cannot be mixed with other insulins.

Degludec seems to be the most improvised insulin analog with a flatter profile, least variability, and a truly once-daily dose with the advantage of flexible timing of administration, lesser nocturnal hypoglycemia compared to glargine \[[Figure 3](#F3){ref-type="fig"}\], and the ability to be mixed with any insulin as well as GLP-1 agonist. However, ideally, degludec too should pass the acid test by conducting equivalent prospective CV trials such as ORIGIN.

![Meta-analysis of all the trials (nocturnal hypoglycaemia outcome)](IJEM-18-784-g014){#F3}
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